# Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

> **NCT03785873** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Nanoliposomal-Irinotecan
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT03785873
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-22
- **Primary completion:** 2024-11-15
- **Final completion:** 2024-11-15
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03785873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03785873, "Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT03785873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*